BridgeBio is demonstrably boosted the development of a new solution for ATTR-CM, leveraging the investigational drug. Initial clinical results indicates promising improvements for patients affected by this debilitating https://attrcm116322.blogripley.com/42951854/bridgebio-progresses-cardiac-amyloidosis-management-with-the-therapy